No products
Product successfully added to your shopping cart
There are 0 items in your cart. There is 1 item in your cart.
Protein Inhibitors
- Protein Control Ligand
- Pathway Inhibitors
- Enzyme Inhibitors
- Kinase Inhibitors
- Protease
- Synthase
- p18
- p38
- p53
- p70
- p90
- Peptidase
- Carboxyl and Decarboxylases
- Ceramide Turnover Enzymes
- Chromatin Modifying Enzymes
- Cyclic Nucleotide Turnover Enzymes
- Glycerophospholipid Turnover Enzymes
- Hydroxylases
- Ubiquitin-Activating Enzyme
- Adenosine Deaminase
- Clathrin
- Nuclease
- p68
- ACE
- COX
- DHFR
- Neprilysin
- NF-κB
- RAF
- RAS
- Reductase
- ROR
- Topoisomerase
- Transferase
- Protein Inhibitors
- Transporter Inhibitors
- Cell Inhibition
- Synthase
- Receptor Tyrosine Phosphatases (RTP)
- AChE
- Peptidase
- Autophagy
- Toll-Like Receptor (TLR)
- Enzyme Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- 5HT Receptors
- Adrenoceptor
- Angiotensin Receptor
- Cannabinoid Receptors
- CCK Receptors
- DA Receptors
- EAA Receptors
- Ghrelin Receptors
- GABA Receptors
- Histamine Receptors
- Leukotriene Receptors
- Metabotropic Glutamate Receptors
- Motilin Receptors
- Muscarinic Receptor
- Neuropeptide Receptors
- Opioid Receptors
- Orexin Receptors
- Orphan Receptors
- Prostanoid Receptors
- Proteinase-Activated Receptors
- Purinergic Receptors
- Ryanodine receptor
- Sigma Receptors
- Thrombin Receptor
- Vaniloid Receptor
- VIP and PACAP Receptors
- Neurotensin Receptors
- Urotensin Receptor
- Imidazoline receptor
- SMO Receptors
- Apelin Receptor
- β-arrestin/β2-adaptin
- KDM4
- Glucocorticoid Receptor
- Laminin Receptor
- AHR
- Amylin Receptor
- Bombesin Receptor
- Bradykinin Receptor
- CFTR
- CGRP Receptor
- CRFR
- Endothelin Receptor
- Ephrin Receptor
- Farnesoid X receptor (FXR)
- Glucagon Receptor
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- PROTAC Linker
- SARS-CoV
View larger Rostafuroxin
AOB2537
CAS No: 156722-18-8
Chemical Name: PST-2238
AOBIOUS launched this product in 2014
CITATIONS - Publications That Use AOBIOUS Product
1) Physiol Rep. 2023 Sep; 11(17): e15820.
2) J of Molecular and Cellular Cardiology Plus
997 Items
Molarity Calculation Cart®
HOW TO ORDER
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $12.75 | Total: $63.75 |
| 1 | 10 | $10.80 | Total: $108.00 |
| 1 | 25 | $9.15 | Total: $228.75 |
| 1 | 50 | $7.80 | Total: $390.00 |
| 1 | 100 | $6.75 | Total: $675.00 |
Data sheet
| Molecular Formula | C23H34O4 |
| Molecular Weight | 374.51 |
| CAS Numbers | 156722-18-8 |
| Storage Condition | 0°C (short term), -20°C (long term), desiccated |
| Solubility | 100 mM in DMSO and to 100 mM in ethanol |
| Purity | 98% by HPLC |
| Synonym | PST 2238 |
| IUPAC/Chemical Name | 3β,5β,14β)-21,23-Epoxy-24-norchola-20,22-diene-3,14,17-triol |
| InChl Key | AEAPORIZZWBIEX-DTBDINHYSA-N |
| SMILES Code | O[C@]4(C5=COC=C5)CC[C@]3(O)[C@]2([H])CC[C@]1([H])C[C@@H](O)CC[C@@](C)1[C@]([H])2CC[C@@]34C |
| References | 1) Ferrari (2006) Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension.Am.J.Physiol.Regul.Integr.Comp.Physiol. 290 529 PMID: 16467500.2) Kirshenbaum et al (2011) Proc.Natl.Acad.Sci.U.S.A. 108 18144 PMID: 22025725 |
More info
Rostafuroxin (also known as PST 2238) is an investigational small molecule being studied for its potential as a blood pressure–lowering (antihypertensive) drug. It’s a derivative of digitoxigenin and is currently not approved for general use.WikipediaInxight DrugsWikipedia
Rostafuroxin offers a promising targeted antihypertensive option that acts at the molecular level to inhibit specific pathways involved in high blood pressure. It provides particular benefits for individuals with genetic variants affecting ouabain activity or the Na⁺/K⁺-ATPase pump. However, it is still in development and not yet widely available.
Targets Ouabain and Na⁺/K⁺-ATPase
Rostafuroxin acts as an antagonist to endogenous ouabain—a hormone-like compound in the body that can raise blood pressure.
It binds to the Na⁺/K⁺-ATPase (also known as the sodium-potassium pump) receptor and prevents ouabain from activating it, but does not interfere with the pump’s normal ion transport function.ScienceDirectInxight DrugsClinPGx
Corrects Na⁺/K⁺-ATPase Dysregulation in Hypertension
In certain types of hypertension—like adducin-related and ouabain-related forms—both kidney and blood vessel cells show abnormal activity of the Na⁺/K⁺-ATPase.
Rostafuroxin restores normal activity of this pump in animal models, helping reverse hypertension caused by these specific molecular changes.PubMedScienceDirectPhysiology Journals
Genetic Precision Approach
Some forms of hypertension arise due to genetic variants in proteins like α-adducin, ADD1, ADD3, or enzymes controlling ouabain levels.
In early clinical trials—like PEARL-HT—rostafuroxin showed better blood pressure reduction compared with losartan (a standard antihypertensive) in Caucasian patients carrying certain genetic profiles (e.g., the P2a genetic profile and LSS rs2254524 AA genotype).NatureResearch Outreach
This demonstrates a precision medicine approach—aligning drug choice with individual genetic makeup for more effective treatment.
